Merck’s investigational Hepatitis C treatment regimen MK-5172/MK-8742 shows robust anti-HCV activity in HIV/HCV co-infected patients

06-03-2014 Business Wire HealthComments (0)

Merck & CoMK-5172PharmaceuticalUSA

Merck today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's MK-5172 and MK-8742.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top